Results 181 to 190 of about 19,342 (221)
Some of the next articles are maybe not open access.
Drug Safety, 2000
The management of cardiac arrhythmias has grown more complex in recent years. Despite the recent focus on nonpharmacological therapy, most clinical arrhythmias are treated with existing antiarrhythmics. Because of the narrow therapeutic index of antiarrhythmic agents, potential drug interactions with other medications are of major clinical importance ...
William H. Frishman +2 more
+5 more sources
The management of cardiac arrhythmias has grown more complex in recent years. Despite the recent focus on nonpharmacological therapy, most clinical arrhythmias are treated with existing antiarrhythmics. Because of the narrow therapeutic index of antiarrhythmic agents, potential drug interactions with other medications are of major clinical importance ...
William H. Frishman +2 more
+5 more sources
Intravenous antiarrhythmic agents
Current Opinion in Cardiology, 2001Intravenous antiarrhythmic drugs can be used as diagnostic tools; for example, adenosine can be used to reveal the underlying rhythm in narrow QRS tachycardia. Newer class III antiarrhythmic agents, like ibutilide and dofetilide, are effective at the conversion of acute atrial fibrillation; however, electrical cardioversion is still the most effective ...
A, Pinter, P, Dorian
openaire +2 more sources
Antiarrhythmic agents and proarrhythmia
Critical Care Medicine, 2000The Vaughn Williams classification divides antiarrhythmic agents into four groups according to their effects on various ion channels. Class I agents block sodium channels and are subdivided into three groups. The use of class Ia agents is gradually on the decline, secondary to lack of a favorable risk/benefit ratio.
G M, Chaudhry, C I, Haffajee
openaire +2 more sources
Class II antiarrhythmic agents
Pharmacology & Therapeutics, 1988The concept of/3-adrenoceptors stems from work published by Ahlquist (1948) following a systematic study of the effects of five catecholamines. He found that these compounds had a specific order of potency in eliciting excitatory responses, such as the contraction of smooth muscle of the iris, blood vessels and sphincters.
J W, Upward, D G, Waller, C F, George
openaire +2 more sources
Chapter 9. Antiarrhythmic Agents
1990Publisher Summary The cardiac arrhythmia suppression trial (CAST) study is designed to test the hypothesis that the suppressing asymptomatic premature ventricular beats with Class I anti-arrhythmic drugs would prolong the survival. The three drugs studied (encainide, flecainide, and moricizine) are chosen because they already had been shown to ...
J ARROWSMITH, P CROSS
openaire +1 more source
Investigational antiarrhythmic agents
Expert Opinion on Investigational Drugs, 2017Introduction: Although there have been important technological advances for the treatment of cardiac arrhythmias (e.g., catheter ablation technology), antiarrhythmic drugs (AADs) remain the cornerstone therapy for the majority of patients with arrhythmias.
Heijman, Jordi +2 more
openaire +1 more source
Moricizine: A Novel Antiarrhythmic Agent
DICP, 1990Moricizine is a phenothiazine derivative with Vaughan Williams class 1 antiarrhythmic properties. It undergoes extensive first-pass metabolism, has a bioavailability of 34–38 percent, and is 95 percent bound to plasma proteins. Moricizine is extensively metabolized and may have pharmacologically active metabolites.
C A, Carnes, J D, Coyle
openaire +2 more sources
Antiarrhythmic Agents During Pregnancy
JAMA: The Journal of the American Medical Association, 1982To the Editor.— In a recent QUESTIONS AND ANSWERS section (1981;245:2105), the issue of antiarrhythmic agents in pregnancy was discussed. Four "traditional" antiarrhythmic agents were recommended for use during pregnancy (quinidine, procainamide hydrochloride, propranolol hydrochloride, and phenytoin sodium).
openaire +2 more sources
New Antiarrhythmic Agents in Pediatrics
Pediatric Clinics of North America, 1989This article reviews recent developments in the pharmacologic management of arrhythmias in children and provides specific information about six newer antiarrhythmic agents. With the current increase in recognition, frequency, and complexity of rhythm disturbances in children, pediatricians can expect to encounter children on these antiarrhythmic ...
C L, Case, D L, Trippel, P C, Gillette
openaire +2 more sources